Tag: acute myeloid leukemia
BVX001 is Well-tolerated in Preclinical Study – Demonstrating a Favorable Safety...
Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).
Study Reinforces the Potential of Pivekimab Sunirine as a Novel Addition...
Initial safety and efficacy findings from an open-label, dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha...
ImmunoGen and Gilead Sciences to Jointly Evaluate Pivekimab Sunirine + Magrolimab...
Gilead Sciences snf ImmunoGen have agreed to jointly evaluate the safety and anti-leukemia activity of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha chain/IL-3 Rα) -targeting...
Actinium Further Strengthens Patent Portfolio for Iomab-B Antibody-radiation Conjugate
Actinium Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its intellectual property portfolio around its lead Phase 3 candidate, I-131 apamistamab (Iomab-B), has been further...
ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for...
This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for patients with hematological malignancies and...
Innate Pharma Confirms Securing Investment to Develop Novel ADC
The French biotechnology company Innate Pharma, which focuses on the discovery as well as the development and commercialization of novel therapeutic antibodies-based therapeutics to...
IMGN779 Demonstrates Favorable Safety Profile with repeat Dosing and no Dose-limiting...
The first-in-human data demonstrate the safety and tolerability of IMGN779, being developed by ImmunoGen, across seven dose levels, with no dose limiting toxicities (DLTs),...
Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators
In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....
Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...
Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...
First Patient Dosed in Phase I Trial of ADCT-301 Trial
Earlier this month ADC Therapeutics, a Swiss-based oncology drug development company, dosed the first patient in a Phase I trial to evaluate ADCT-301, also...
